SCHEMBL23875007

SCHEMBL23875007

COc1ccc(F)cc1-c1c(Cl)ccc(OCc2ccccc2)c1C(=O)N=C(SC)SC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 2/20 0.41
FFAR1 O14842 1/20 0.41
STK10 O94804 1/20 0.40
SLK Q9H2G2 1/20 0.40
HPGD P15428 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SLC9A1 P19634 1/20 0.38
PTGER1 P34995 1/20 0.38
MTNR1A P48039 2/20 0.38
MTNR1B P49286 2/20 0.38
MRGPRX4 Q96LA9 3/20 0.37
SMPD1 P17405 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC8 Q9BY41 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21884552 0.86 FFAR1 (0.48) FFAR4FFAR1STK10SLKHPGD
SCHEMBL23875005 0.82 STK10 (0.41) FFAR4FFAR1STK10SLKHPGD
SCHEMBL21884805 0.76 STK10 (0.46) FFAR4FFAR1STK10SLKHPGD
SCHEMBL21884553 0.74 STK10 (0.38) FFAR4FFAR1STK10SLKHPGD
SCHEMBL23875039 0.74 FFAR1 (0.39) FFAR4FFAR1STK10SLKHPGD
SCHEMBL23875027 0.70 XDH (0.42) FFAR4FFAR1SMN1; SMN2ALDH1A1NPC1
SCHEMBL23875040 0.70 CCNT1 (0.41) FFAR4FFAR1HPGDSMN1; SMN2ALDH1A1
SCHEMBL23875015 0.68 MRGPRX4 (0.46) FFAR4FFAR1STK10SLKHPGD
SCHEMBL21884784 0.67 XDH (0.41) MRGPRX4
SCHEMBL21667956 0.67 FFAR1 (0.58) FFAR4FFAR1HPGDSMN1; SMN2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210371403-A1 SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS JNANA THERAPEUTICS INC. 2021-12-02 US disclosed
US-20210299070-A1 METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY JNANA THERAPEUTICS INC. 2021-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210299070-A1 METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY SLC19A1, SLC1A5, SLC1A2 FFAR4 3825/4885FFAR1 2709/4885STK10 3618/4885
US-20210371403-A1 SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS SNRPE, G3BP1, G3BP2 FFAR4 4834/4885FFAR1 4719/4885STK10 2265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.